Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorCHASTEL, Adrien
dc.contributor.authorWORM, Dennis J.
hal.structure.identifierChimie et Biologie des Membranes et des Nanoobjets [CBMN]
dc.contributor.authorALVES, Isabel
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorVIMONT, Delphine
dc.contributor.authorPETREL, Melina
dc.contributor.authorFERNANDEZ, Samantha
dc.contributor.authorGARRIGUE, Philippe
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorFERNANDEZ, Philippe
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorHINDIE, Elif
dc.contributor.authorBECK-SICKINGER, Annette G.
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorMORGAT, Clement
dc.date.accessioned2022-10-11T12:57:30Z
dc.date.available2022-10-11T12:57:30Z
dc.date.issued2020-03-02
dc.identifier.issn2191-219Xen_US
dc.identifier.urioai:crossref.org:10.1186/s13550-020-0612-8
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/148379
dc.description.abstractEnBackground: Targeting G protein-coupled receptors on the surface of cancer cells with peptide ligands is a promising concept for the selective tumor delivery of therapeutically active cargos, including radiometals for targeted radionuclide therapy (TRT). Recently, the radiolanthanide terbium-161 (161Tb) gained significant interest for TRT application, since it decays with medium-energy β-radiation but also emits a significant amount of conversion and Auger electrons with short tissue penetration range. The therapeutic efficiency of radiometals emitting Auger electrons, like 161Tb, can therefore be highly boosted by an additional subcellular delivery into the nucleus, in order to facilitate maximum dose deposition to the DNA. In this study, we describe the design of a multifunctional, radiolabeled neuropeptide-Y (NPY) conjugate, to address radiolanthanides to the nucleus of cells naturally overexpressing the human Y1 receptor (hY1R). By using solid-phase peptide synthesis, the hY1R-preferring [F7,P34]-NPY was modified with a fatty acid, a cathepsin B-cleavable linker, followed by a nuclear localization sequence (NLS), and a DOTA chelator (compound pb12). In this proof-of-concept study, labeling was performed with either native terbium-159 (natTb), as surrogate for 161Tb, or with indium-111 (111In). Results: [natTb]Tb-pb12 showed a preserved high binding affinity to endogenous hY1R on MCF-7 cells and was able to induce receptor activation and internalization similar to the hY1R-preferring [F7,P34]-NPY. Specific internalization of the 111In-labeled conjugate into MCF-7 cells was observed, and importantly, time-dependent nuclear uptake of 111In was demonstrated. Study of metabolic stability showed that the peptide is insufficiently stable in human plasma. This was confirmed by injection of [111In]In-pb12 in nude mice bearing MCF-7 xenograft which showed specific uptake only at very early time point. Conclusion: The multifunctional NPY conjugate with a releasable DOTA-NLS unit represents a promising concept for enhanced TRT with Auger electron-emitting radiolanthanides. Our research is now focusing on improving the reported concept with respect to the poor plasmatic stability of this promising radiopeptide.
dc.description.sponsorshipTranslational Research and Advanced Imaging Laboratory - ANR-10-LABX-0057en_US
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.sourcecrossref
dc.subject.en161Tb
dc.subject.enNeuropeptide-Y
dc.subject.enSub-cellular delivery
dc.subject.enAuger-emitter
dc.subject.enBreast cancer
dc.title.enDesign, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s13550-020-0612-8en_US
dc.subject.halSciences du Vivant [q-bio]en_US
dc.identifier.pubmed32124111en_US
bordeaux.journalEJNMMI Researchen_US
bordeaux.volume10en_US
bordeaux.hal.laboratoriesInstitut de neurosciences cognitives et intégratives d'Aquitaine (INCIA) - UMR 5287en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.institutionBordeaux INP
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de la Rechercheen_US
bordeaux.identifier.funderIDCentre National de la Recherche Scientifiqueen_US
bordeaux.identifier.funderIDUniversité de Bordeauxen_US
bordeaux.identifier.funderIDConseil Régional Aquitaineen_US
bordeaux.import.sourcedissemin
hal.identifierhal-03082079
hal.version1
hal.exportfalse
workflow.import.sourcedissemin
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=EJNMMI%20Research&rft.date=2020-03-02&rft.volume=10&rft.issue=1&rft.eissn=2191-219X&rft.issn=2191-219X&rft.au=CHASTEL,%20Adrien&WORM,%20Dennis%20J.&ALVES,%20Isabel&VIMONT,%20Delphine&PETREL,%20Melina&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée